Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

@article{Jacobs2016MonoclonalAA,
  title={Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence},
  author={I. Jacobs and Danielle Petersel and L. Shane and Chee-Keng Ng and C. Kirchhoff and G. Finch and S. Lula},
  journal={Biodrugs},
  year={2016},
  volume={30},
  pages={489 - 523}
}
  • I. Jacobs, Danielle Petersel, +4 authors S. Lula
  • Published 2016
  • Medicine
  • Biodrugs
  • BackgroundDespite regulatory efforts to formalize guidance policies on biosimilars, there remains a need to educate healthcare stakeholders on the acknowledged definition of biosimilarity and the data that underpin it. [...] Key MethodMethodsMEDLINE, Embase, and ISI Web of Science were searched to September 2015. Conference proceedings (n = 17) were searched 2012 to July 2015. Included studies were categorized by originator, study type, and indication.Expand Abstract
    33 Citations

    Figures, Tables, and Topics from this paper

    Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
    • 29
    • PDF
    Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
    • 4
    Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
    • 21
    • PDF
    Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    • 11
    Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    • 4
    • Highly Influenced
    Improving Access to Cancer Treatments: The Role of Biosimilars
    • 27

    References

    SHOWING 1-10 OF 378 REFERENCES
    Biosimilar monoclonal antibodies: the scientific basis for extrapolation
    • 21
    Regulatory considerations in oncologic biosimilar drug development
    • 20
    Rituximab biosimilars
    • 25
    Clinical considerations for biosimilar antibodies
    • H. Mellstedt
    • Medicine
    • EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
    • 2013
    • 39
    • PDF
    Biosimilars: Rationale and current regulatory landscape.
    • E. Olech
    • Medicine
    • Seminars in arthritis and rheumatism
    • 2016
    • 32
    • Highly Influential
    • PDF
    NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    • 135
    • PDF
    Biosimilar safety considerations in clinical practice.
    • 21
    Biosimilars in the therapy of inflammatory bowel diseases
    • 34